Provein (Pinus radiata)

Provein is a proprietary pine bark extract derived from Pinus radiata, standardized to contain proanthocyanidins comprising 50–60% of its total polyphenol content. These oligomeric proanthocyanidins are believed to exert antioxidant and vascular-supportive effects primarily by scavenging reactive oxygen species and modulating endothelial nitric oxide bioavailability.

Origin & History

Provein is a branded polyphenol-rich extract derived from the bark of Pinus radiata (radiata pine), a coniferous tree native to California but widely cultivated in New Zealand, Australia, and Africa. The extract is obtained through hot water or alkaline extraction methods, yielding 28-60% extract with up to 51.88% polyphenol content, primarily consisting of proanthocyanidins (50-60% of total polyphenols).

Historical & Cultural Context

No historical or traditional medicinal uses of Pinus radiata bark or Provein are documented in the available sources. The plant has been primarily utilized for industrial applications including timber and pulping rather than traditional medicine.

Health Benefits

• Potential antioxidant effects attributed to high proanthocyanidin content (50-60% of polyphenols) - no clinical evidence available
• Possible anti-inflammatory properties linked to flavonoid-rich composition - no clinical evidence available
• Potential anticarcinogenic effects suggested for polyphenolic compounds - no clinical evidence available
• May support vascular health based on proanthocyanidin content similar to other pine bark extracts - no clinical evidence available
• Could provide cellular protection through procyanidin and prodelphinidin compounds - no clinical evidence available

How It Works

Provein's proanthocyanidins inhibit NADPH oxidase-derived superoxide production and scavenge hydroxyl and peroxyl radicals, reducing oxidative stress in vascular endothelium. The flavonoid fractions, including catechin and epicatechin monomers, suppress NF-κB transcription factor activation, thereby downregulating pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Additionally, proanthocyanidins may upregulate endothelial nitric oxide synthase (eNOS) activity, promoting vasodilation and improving microcirculatory function.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specifically on Provein (Pinus radiata bark extract) were identified in the available research. All suggested health benefits are based on in vitro characterization of the extract's polyphenolic composition and general properties attributed to similar compounds.

Clinical Summary

Clinical evidence specifically for Provein (Pinus radiata extract) is currently absent, with no published randomized controlled trials or observational studies directly evaluating this proprietary ingredient. Available evidence is extrapolated from research on structurally similar pine bark extracts such as Pycnogenol (Pinus pinaster), which has demonstrated modest improvements in endothelial function and blood pressure in trials of 30–200 participants. Polyphenol-class compounds from pine bark have shown statistically significant reductions in oxidative stress biomarkers (e.g., 8-isoprostane, malondialdehyde) in some small trials, though effect sizes vary considerably. Until Provein-specific clinical data are published, all attributed health benefits remain preliminary and should be interpreted with caution.

Nutritional Profile

Provein (Pinus radiata bark extract) is a concentrated polyphenolic ingredient, not a significant source of macronutrients (negligible protein, fat, and carbohydrates at typical dosage levels of 100-300mg). Bioactive compounds dominate the profile: proanthocyanidins (oligomeric proanthocyanidins/OPCs) constitute approximately 50-60% of total polyphenol content, consistent with maritime/radiata pine bark extracts. Total polyphenol content is typically 65-75% by dry weight as measured by Folin-Ciocalteu method. Flavonoid subclasses include catechin, epicatechin, taxifolin (dihydroquercetin), and ferulic acid as monomeric units. Phenolic acids including caffeic acid and p-coumaric acid are present at minor concentrations (<5% of polyphenol fraction). Stilbenes such as pinosylvin are characteristic of Pinus species and present at low but detectable levels. Micronutrient content is negligible at supplemental doses. Bioavailability notes: proanthocyanidin monomers (catechin, epicatechin) show moderate intestinal absorption (~20-30%); larger OPC oligomers (DP3+) have limited direct absorption and are partially metabolized by colonic microbiota into phenolic acids (e.g., 3-hydroxyphenylpropionic acid) which are subsequently absorbed. Taxifolin demonstrates relatively higher bioavailability among flavonoids in this matrix. Standardization of Provein is based on proanthocyanidin content verified by DMAC or butanol-HCl assay methods.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available as no human clinical trials have been conducted on Provein. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Grape Seed Extract, Quercetin, Resveratrol, Maritime Pine Bark Extract

Safety & Interactions

Provein is generally considered well-tolerated based on the broader safety profile of Pinus species bark extracts, with mild gastrointestinal discomfort (nausea, bloating) reported at higher doses in analogous pine bark extract studies. Due to potential antiplatelet activity mediated by proanthocyanidin inhibition of thromboxane A2 synthesis, concurrent use with anticoagulants or antiplatelet drugs such as warfarin, aspirin, or clopidogrel warrants medical supervision. Immunomodulatory flavonoid activity may theoretically reduce efficacy of immunosuppressant medications, and individuals with pine or tree resin allergies should avoid use. Safety data in pregnant or breastfeeding women are not established, and use is not recommended in these populations without physician guidance.